Shanghai Labway Clinical Laboratory (301060.SZ) shareholder Hailan Group plans to reduce its shareholding by no more than 2%.
Lanwei Medical (301060.SZ) announced that its shareholder Hailan Group Co., Ltd. (referred to as "Hailan Group") plans to...
Announcement from Shanghai Labway Clinical Laboratory (301060.SZ): The company's shareholder, Hailan Group Limited (referred to as "Hailan Group"), plans to reduce its holdings of the company's shares by no more than 7.9704 million shares (representing 2.00% of the total share capital excluding shares held in the company's repurchase special account) through centralized bidding and/or block trading within 3 months after 15 trading days from the disclosure of this reduction plan.
Related Articles
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
